Market Research Logo

Diabetic Neuropathic Pain - Pipeline Review, H2 2015

Diabetic Neuropathic Pain - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H2 2015’, provides an overview of the Diabetic Neuropathic Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Neuropathic Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathic Pain Overview
Therapeutics Development
Pipeline Products for Diabetic Neuropathic Pain - Overview
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis
Diabetic Neuropathic Pain - Therapeutics under Development by Companies
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
Diabetic Neuropathic Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Neuropathic Pain - Products under Development by Companies
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
AstraZeneca Plc
BioDelivery Sciences International, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Mertiva AB
Novaremed
Pharmaleads
RAPID Pharmaceuticals AG
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Theravasc, Inc.
Diabetic Neuropathic Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(diclofenac sodium + triclocarban) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-1069562 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-3662 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-5213 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duloxetine hydrochloride DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-52862 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GERPOOI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC-17536 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HC-030031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kindolor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mepivacaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NG2-GAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRD-135SE1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGN-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-37 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAP-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAP-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sodium nitrite SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Neuropathic Pain - Recent Pipeline Updates
Diabetic Neuropathic Pain - Dormant Projects
Diabetic Neuropathic Pain - Discontinued Products
Diabetic Neuropathic Pain - Product Development Milestones
Featured News & Press Releases
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37
Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy
Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H2 2015
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2015
Diabetic Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2015
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2015
Diabetic Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Diabetic Neuropathic Pain - Pipeline by Dong-A Socio Group, H2 2015
Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2015
Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2015
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2015
Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H2 2015
Diabetic Neuropathic Pain - Pipeline by Novaremed, H2 2015
Diabetic Neuropathic Pain - Pipeline by Pharmaleads , H2 2015
Diabetic Neuropathic Pain - Pipeline by RAPID Pharmaceuticals AG, H2 2015
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2015
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015
Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2015
Diabetic Neuropathic Pain - Dormant Projects, H2 2015
Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H2 2015
Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H2 2015
Diabetic Neuropathic Pain - Discontinued Products, H2 2015
Diabetic Neuropathic Pain - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Diabetic Neuropathic Pain, H2 2015
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report